Carlos Encarnacion, MD
Medical Oncology · Waco, TXNPI 1245273838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 84 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$269
- Medtronic$182
- Novartis$170
- Adaptive Biotechnologies Corporation$170
- AstraZeneca$154
- Mirati Therapeutics, Inc.$130
- plus $1K from 31 others
Across 295 payments — averaging $2494.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$237K
- E.r. Squibb & Sons, L.L.C.$215K
- Eisai Inc.$133K
- Sanofi US Services Inc.$66K
- Genentech, Inc.$60K
- F. Hoffmann-la Roche AG$15K
- plus $11K from 2 others
What the payments were for
- Food & beverage$2,40798%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 8 | $269 |
| Medtronic | 2 | $182 |
| Novartis | 7 | $170 |
| Adaptive Biotechnologies Corporation | 5 | $170 |
| AstraZeneca | 3 | $154 |
| Mirati Therapeutics, Inc. | 3 | $130 |
| Merck | 5 | $110 |
| Clovis Oncology, Inc. | 1 | $110 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| E.r. Squibb & Sons, L.L.C. | 1 | $82 |
| Gilead(2 entities) | 3 | $75 |
| Astellas Pharma US Inc | 3 | $75 |
| Lilly USA, LLC | 1 | $71 |
| Pharmaessentia USA Corporation | 2 | $64 |
| Myriad Genetic Laboratories, Inc. | 2 | $62 |
| GSK | 3 | $56 |
| Sanofi | 3 | $55 |
| Taiho Oncology, Inc. | 2 | $55 |
| Incyte Corporation | 2 | $50 |
| Sobi, Inc | 2 | $39 |
| EMD Serono, Inc. | 2 | $37 |
| Pfizer | 2 | $36 |
| Tempus AI, Inc | 2 | $36 |
| Medinc Of Texas | 2 | $36 |
| Seagen Inc. | 2 | $30 |
| Bristol Myers Squibb | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$160
- clonoSEQ$117
- Rubraca$110
- IMFINZI$106
How this compares
$2,460 in reported general payments places this provider in the 35th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 25 | $48,658 |
| Letrozole | 194 | $2,886 |
| Exemestane | 33 | $2,843 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $1,900 |
| Megestrol Acetate | 17 | $774 |
| Hydroxyurea | 24 | $573 |
| Tamoxifen Citrate | 28 | $531 |
| Gabapentin | 18 | $468 |
| Dexamethasone | 32 | $451 |
| Anastrozole | 22 | $397 |
| Ondansetron OdtOndansetron | 11 | $225 |
| Prednisone | 37 | $148 |
| Acyclovir | 19 | $128 |
| Tramadol Hcl | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Waco
- Carl ChakmakjianWaco$273K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.